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Abstract 
Factor (F)XIII is a tranglutaminase enzyme that catalyses the formation of -(-glutamyl)lysyl 
isopeptide bonds into protein substrates. The plasma form, FXIIIA2B2 has an established function in 
hemostasis, where its primary substrate is fibrin.  A deficiency in FXIII manifests as a severe bleeding 
diathesis underscoring its importance in this pathway.  The cellular form of the enzyme, a 
homodimer of the A subunits, denoted FXIII-A, has not been studied in as extensive detail.  FXIII-A 
was generally perceived to remain intracellular, due to the lack of a classical signal peptide for its 
release.  In the last decade emerging evidence has revealed that this diverse transglutaminase can 
be externalised from cells, by an as yet unknown mechanism, and can cross-link extracellular 
substrates and participate in a number of diverse pathways.  The FXIII-A gene (F13A1) is expressed in 
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cells of bone marrow and mesenchymal lineage, notably megakaryocytes, monocytes/macrophages, 
dendritic cells, chrondrocytes, osteoblasts and preadipocytes.  The biological processes that FXIII-A is 
coupled with reflect its expression in these cell types, such as wound healing, phagocytosis and bone 
and matrix remodelling.  This review describes the mounting evidence that this cellular 
transglutaminase can be externalised, usually in response to stimuli, and participate in extracellular 
cross-linking reactions.  A corollary of being involved in these biological pathways is the participation 
of FXIII-A in pathological processes.  In conclusion, the functions of this transglutaminase extend far 
beyond its role in hemostasis and our understanding of this enzyme in terms of its secretion, 
regulation and substrates is in its infancy.   
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Introduction 
In 1948 Laki and Lorand characterised a labile component of blood that when combined with Ca2+ 
rendered a clot insoluble [1]. The protein was later isolated and named fibrin stabilising protein [2].  
Duckert et al [3] then reported that deficiency of fibrin stabilizing factor manifests as a severe 
bleeding diathesis.  Subsequently in 1963, the International Committee on Blood Clotting Factors 
acknowledged this protein as a clotting factor and termed it factor XIII (FXIII).  Our knowledge of FXIII 
has progressed significantly since these early informative observations.  It is now clear that in 
addition to the essential role of FXIII in hemostasis it functions in a variety of other systems ranging 
from wound healing and angiogenesis [4] to stabilisation of the bone matrix [5]. Once activated FXIII 
(FXIIIa) elicits transamidase activity that introduces -(-glutamyl)lysyl isopeptide cross-links into 
protein substrates. It can incorporate cross-links into single protein substrates, such as fibrin, or can 
cross-link different proteins to each other, which can impact on their biological function [6].   
 
In plasma, FXIII exists as a zymogen heterotetramer (FXIII-A2B2) [7] with two catalytic A subunits and 
two inhibitory carrier B subunits. [8].  FXIII-B is synthesised and secreted by hepatocytes [9, 10], 
however the source of plasma FXIII-A subunit has been debated for some years.  The gene, F13A1, is 
largely expressed in cell of bone marrow origin, but it lacks an identifiable endoplasmic reticulum 
(ER) signal sequence and is excluded from the classical ER-Golgi pathway in nucleated cells [11].  
Platelets were projected to be the source of the FXIII-A subunit in plasma [12, 13], but this was ruled 
out, as levels were unchanged in thrombocytopenic mice [14].  Recent observations, in tissue 
specific mouse knockouts of FXIII-A, now pinpoint resident tissue macrophages as the cellular source 
of plasma FXIII-A [15].  Plasma FXIII-A2B2 requires the concerted action of thrombin and calcium to 
be activated [16, 17]. The activation peptides which flank each of the FXIII-A subunits are initially 
cleaved by thrombin, which destabilizes the interaction between the FXIII-A and FXIII-B subunits 
[18]. The subsequent binding of calcium ions to defined sites on the FXIII-A subunits instigates 
dissociation of the FXIII-B subunits and activation peptides [19]. 
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The cellular form of FXIII is a homodimer of the A-subunits, termed FXIII-A throughout this review 
[20].  Cellular FXIII-A is non-proteolytically activated by modest increases in intracellular Ca2+ 
concentrations [21, 22].  FXIII-A has been localized in a wide variety of different cells including 
platelets [23-25], megakaryocytes [26] monocytes [27, 28], circulating [27, 29], and tissue 
macrophages [29], dendritic cells [30], chondrocytes [31-33] osteoblasts [5] and preadipocytes [34].  
The mechanism of FXIII-A release from these cells remains an enigma, due to the lack of signal 
sequence as stated, and it is also absent from the ER-Golgi secretory pathway in nucleated cells [11]. 
However, FXIII-A in monocyte-macrophages is reportedly directed to the plasma membrane in 
association with Golgi vesicles [14] indicating that it is secreted via an alternative pathway. This 
review will focus on the multifarious actions of cellular FXIII-A and discuss whether it is capable of 
mediating extracellular cross-linking as well as intracellular functions despite its clear lack of a signal 
peptide for secretion. 
 
FXIII-A in Platelets  
Platelets harbour remarkably high concentrations of FXIII-A within their cytoplasm [35, 36], with a 
single platelet accruing 60 ± 10 fg, corresponding to 3% of total platelet protein [37].  -granules 
reportedly contain a minor pool of FXIII in the A2B2 form which is endocytosed from plasma 
alongside fibrinogen [35, 38], however the concentrations are so low  it is often not detectable in the 
platelet secretome [39, 40].  Early studies on platelet FXIII-A concluded that it was not involved in 
haemostasis, as it did not form part of the platelet secretome [39], but our recent observations 
indicate that FXIII-A is translocated from the cytoplasm to the surface of activated platelets where is 
actively retained [40].      
 
Platelet FXIII-A in hemostasis 
The role of plasma FXIIIA2B2 in haemostasis is well-established; it confers mechanical stability to 
thrombi by cross-linking the - and -chains of fibrin, and provides protection against fibrinolytic 
breakdown by cross-linking inhibitors of fibrinolysis to fibrin [41-43]. Our laboratory has shown that 
flow is required to visualize the impact of FXIIIA2B2 on fibrinolysis [44] and that the antifibrinolytic 
action of this transglutaminase is mediated exclusively by cross-linking 2-antiplasmin (2AP) to 
fibrin [45].  Rijken and colleagues subsequently reported that compaction or retraction of fibrin clots 
reveals the strong antifibrinolytic effect of FXIIIA2B2 [46].  The authors also confirm our observations 
that cross-linking of 2AP is required for the antifibrinolytic effect of FXIII to be visualised rather 
than by fibrin-fibrin cross-links [46]. Plasma FXIIIA2B2, but not platelet FXIII-A, also aids in the 
retention of red blood cells in clots through fibrin -chain cross-linking which has a direct impact on 
the overall size of clots [47-49].  
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Platelet FXIII-A was previously shown to stabilize clots, by inducing the formation of high molecular 
weight -dimer and -polymer [50-54] and cross-linking 2AP to fibrin [50, 53]. The conundrum is 
that FXIII-A was not found within the secretome of platelets.  Our laboratory has now shown that 
strong agonist stimulation of platelets induces translocation of FXIII-A from the cytoplasm to the 
platelet membrane where it is actively retained and can participate in extracellular cross-linking 
reactions [40]. The intensity of FXIII-A staining on the surface of activated platelets increases as a 
function of time, particularly in those platelets directly associated with collagen fibres (Figure 1A).  
Our work clearly highlights a role for FXIII-A, externalised during platelet activation, in stabilizing 
thrombi via cross-linking of 2AP to fibrin [40].  The relative contribution of plasma FXIIIA2B2 versus 
platelet-derived FXIII-A to thrombus stability requires clarification, but it is unlikely to be uniform 
throughout the thrombus, with the balance tipping toward FXIII-A in platelet-rich areas of the 
hemostatic plug, where solute transport of plasma FXIIIA2B2 is low.  
 
Distribution of FXIII-A on the activated platelet surface is dependent on the subpopulation of 
platelets (Figure 1B), with PS-negative or spread platelets exhibiting diffuse staining across the 
membrane with a high concentration over the granulomere [40].  In PS-positive procoagulant 
platelets, FXIII-A was present only in the protruding ‘cap’ [40]. These ‘caps’ bind a number of other 
hemostatic proteins including fibrinogen [55], plasminogen and PAI-1 [56]. The ‘caps’ of platelets 
have recently been described as the ‘platelet body’ which the authors speculate is the remnant of 
organelles following ballooning of the platelet following strong agonist stimulation [57].  Ballooning 
transpires due to expansion of the platelet membrane, as a result of rapid influx of water and Na+ 
and Cl- ions. These platelets bind both procoagulant factor Xa and factor Va to the ballooned area 
and the platelet body thereby augmenting thrombin generation [58]. The collection of both 
procoagulant and pro- and anti-fibrinolytic proteins in these PS-positive platelets suggests they 
participate not only thrombus formation, but also the stability and breakdown of the thrombus.  
FXIII-A also functions in the formation of PS-positive platelets [59], by acting in concert with calpain 
to reduce the adhesive function of IIbβ3, in a process that appears to be a prerequisite for their 
formation.  
 
The method of externalization of platelet FXIII-A remains to be elucidated, but clearly occurs in 
response to external stimuli [40]. Reduced levels of FXIII-A were detected on stimulation of platelets 
with TRAP-6, compared to thrombin, and when platelets were treated with the Gly-Pro-Arg-Pro 
peptide, which inhibits fibrin polymerisation. The connection between platelet-associated fibrin and 
FXIII-A exposure suggests that IIbβ3 may serve as a ‘bridge’ for FXIII-A to traverse to access the 
fibrin network [40].  Fibrin associated directly with the platelet surface is exceptionally resilient to 
fibrinolysis [56, 60-63], suggesting that platelet-derived FXIII-A and other anti-fibrinolytic proteins 
contribute to this heightened resistance at least in the early stages of thrombus formation.  
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Platelet FXIII-A in clot retraction 
Clot retraction is the process by which fully-formed clots are compacted to limit vessel blockage and 
prevent leakage from the wound site. Platelets operate contractile machinery to reel in the 
surrounding fibrin network, expedited by bi-directional IIbβ3 signalling [64]. The integrin IIbβ3 
acts as a molecular bridge between extracellular fibrinogen and the intracellular actin cytoskeleton 
via sphingomyelin-rich lipid rafts [65]. The cytoskeleton interacts with the 3 subunit tails via the 
adapter proteins talin and vinculin [66]. During clot retraction, fibrin bound to IIbβ3 triggers 
outside-in signalling [67], resulting in the contraction of the actin cytoskeleton.  FXIIIA2B2 contributes 
to the strength and rigidity of the condensed clot by cross-linking fibrin, and by enhancing platelet 
spreading [68]. Conflicting evidence exists on the effects of platelet FXIII-A on clot retraction. Early 
reports found that clot retraction was normal in FXIII-deficient patients [69-71]. More recently, 
Kasahara et al., [65, 72], have demonstrated that clot retraction was significantly impaired in the 
absence of platelet FXIII-A transglutaminase activity in PRP from FXIII-A knockout mice [65, 72]. In 
contrast, Kattula et al., [49] found that platelet FXIII-A did not contribute to the weight of clots 
formed from reconstituted FXIII-depleted plasma reconstituted with red blood cells compared with 
those containing FXIII-deficient platelets. Methodological differences in the two studies may account 
for these reported discrepancies, however, it is evident that further studies are required to confirm 
the role of platelet FXIII-A functions in clot retraction in vivo.   
 
Other roles of platelet FXIII-A 
The adhesive ability of IIbβ3 is thought to be negatively regulated by FXIII-A and calpain, which 
limits platelet aggregate formation and thrombus growth [59].  These observations were made 
primarily in collagen-adherent platelets with prolonged elevations in cytosolic calcium, leading to a 
specific reduction in IIbβ3 adhesive function.  During thrombus formation, a number of 
phenotypically different platelet populations arise [59, 73-75]. These populations play different roles 
in the regulation of the thrombus microenvironment. Adherent platelets, with activated IIbβ3, bind 
other platelets and fibrin and ensure thrombus stability [76], while procoagulant platelets lack 
functional IIbβ3.  Platelet FXIII-A also drives formation of a specific subtype of procoagulant 
platelets that retain an alpha-granule protein ‘coat’ on their surface [77-79].  Transglutaminase 
activity cross-links -granule proteins to serotonin where they can then be retained on the platelet 
surface by binding to low affinity serotonin binding sites on fibrinogen or thrombospondin [77, 79].  
It has been proposed that platelet FXIII-A is not a requirement for generation of coated platelets, 
due to their formation in FXIII deficient mice [80].  However, this could be due to a compensatory 
upregulation of other transglutaminases in FXIII-A deficient platelets [80].  In line with this FXIII-A 
deficient platelets have also been found to accelerate cross-linking [53].  
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Under low shear conditions fibrin formation on platelets forms a ‘star-like’ pattern on the platelet 
surface [81].  FXIII-A and IIbβ3 play synergistic roles in aiding formation of these fibrin protrusions. 
In the absence of FXIII-A and IIbβ3, fibrin formation still occurs on the platelet surface, however 
fibres are orientated in the direction of flow [78], suggesting that early cross-links facilitate fibrin 
polymerisation against the direction of flow. 
 
It has been suggested that FXIII-A functions in formation of protrusions such as filopodia and 
lammelipodia which aid in platelet adhesion, spreading and clot retraction [82]. A number of 
proteins involved in cytoskeletal remodelling are cross-linked by FXIII-A, including; actin [83, 84], 
GPIIb, GPIII, myosin, tropomyosin [84], talin, vinculin, filamin [82], and Thymosin beta4 [85].  FXIII-A 
associates with the cytoskeleton upon platelet activation, however, this is dependent on actin 
polymerisation, as the phallotoxin cytochalasin D inhibited this translocation [82].  Interestingly, 
cross-linking of vinculin was dependent on aggregation.  Vinculin cannot be cross-linked to itself, but 
is cross-linked to a number of other cytoskeletal proteins [82], suggesting FXIII-A may localise key 
cytoskeletal proteins during remodelling.  FXIII-A directly associates with HSP27 in activated platelets 
[86].  HSP27 functions as a molecular chaperone and rapidly interacts with the actin cytoskeleton 
upon platelet stimulation.  It is plausible that HSP27 acts as a chaperone for translocation of FXIII-A 
from the platelet cytoplasm to the outer membrane via the actin cytoskeleton.  
 
FXIII-A in leukocytes 
FXIII-A is located in the cytoplasm of macrophages and monocytes [87], Leukocyte FXIII-A has been 
implicated in a number of intra-and extracellular processes, but as yet there is no defined route of 
externalisation  
 
FXIII-A is expressed on the cell surface of monocytes and macrophages [88] in response to 
stimulation with certain immune modulators, which is akin to the situation in platelets [40]. The 
expression of FXIII-A in macrophages is dynamic in nature and can be altered in response to the 
external stimulus and the phenotype of the activated macrophage.  Macrophages can be 
‘alternatively’ or ‘classically’ activated depending on the activating stimulus. ‘Classically activated’ or 
M1 macrophages are generated in response to stimulation with the immune mediators, IFN-, LPS or 
TNF [89].  These pro-inflammatory ‘type 1’ macrophages [90] tend to exhibit down-regulation of 
FXIII-A [91, 92]. ‘Alternatively activated’, or M2 macrophages are stimulated in response to anti-
inflammatory mediators, such as IL-4 and IL-13 [90].  M2 macrophages are reported to function in 
matrix remodelling, wound healing, allergy and parasite killing [89] and it is this subtype of 
macrophages that reveal upregulation of FXIII-A [92-94]. The selective expression of FXIII-A in M2 
macrophages is in line with the capacity of this transglutaminase to act as an anti-inflammatory and 
pro- wound healing molecule. 
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Phagocytosis is the active ingestion and breakdown of microbes or other foreign particles by cells 
such as monocytes and macrophages.  Phagocytic processes are driven by a finely controlled 
rearrangement of the actin cytoskeleton [95].  Considering the key role of FXIII-A in regulating 
cytoskeletal proteins it is perhaps not surprising that it is directly linked to this process [82-84]. 
Studies have indicated that FXIII-A activity may play a role in increasing the amount of phagocytosis 
in monocytes and macrophages [96].  
 
Phagocytosis is positively correlated with FXIII-A expression in myelomonocytic cells [97].  In 
accordance with this Fc and complement receptor mediated phagocytosis is impaired in monocytes 
and macrophages following inhibition of FXIII-A and in FXIII-A-deficient mice [96]. FXIII-A is known to 
be upregulated during the maturation of monocyte-derived dendritic cells and actively assists 
migration of these cells [98].  Together these data implicate FXIII-A in the phagocytic and/or 
migration capacity of these cells, however there may be a degree of redundancy in the system, as 
phagocytosis is only slightly impaired in the absence of FXIII-A [96].  
 
The role of cellular FXIII-A in lymphocytes in haemostasis has not been widely explored, however 
macrophages and monocytes are able to cross-link fibrin- and -chains [88, 99], suggesting a 
potential role in thrombus stabilisation. Interestingly, thrombin treatment of monocytes does not 
augment exposure of FXIII-A [88], suggesting these cells may contribute to haemostasis in a situation 
where there is also an increase in the type 2 immune response, for example in a wound healing 
capacity. 
 
FXIII-A in bone 
Bone is a dynamic mineralized tissue which undergoes continuous remodelling in the form of bone 
resorption by osteoclasts and formation by osteoblasts. The processes of bone formation and 
resorption are influenced by many chemical and mechanical factors and an imbalance can severely 
impact on bone quality [100].  FXIII-A is present in a number of cell types in mineralized tissues 
including chondrocytes [31-33], osteocytes [101] and osteoblasts [5, 101] where it is both expressed 
on the cell surface and secreted into the extracellular matrix.  FXIII-A contributes to the formation 
and stabilisation of connective tissue in bone by cross-linking a number of different substrates. 
Secreted osteoblast FXIII-A aids in the incorporation of fibronectin into the bone matrix [102, 103] 
thereby promoting formation of an insoluble matrix.  This matrix forms a scaffold for other proteins 
to adhere to, including type 1 collagen [104].  Surface-associated osteoblast FXIII-A is involved in 
stabilizing the interaction between microtubules and the plasma membrane, which in turn enhances 
the secretion of collagen [102, 105-107].  Collagen is the principal component of bone matrix and it 
appears that both FXIII-A activity and fibronectin are essential for normal collagen deposition [102, 
103].  Extracellular collagen is a prerequisite for secretion of FXIII-A from osteoblasts and in line with 
this observation, increased levels of collagen enhance expression of FXIII-A mRNA [106].  Osteoblast 
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FXIII-A also contributes to bone quality where its absence has a negative effect on alkaline 
phosphatase activity, lysyl oxidase levels and bone mineralisation. On an intracellular level, a 
regulatory role for FXIII-A and other transglutaminase enzymes has been identified in the different 
stages of osteoclastogenesis, including differentiation, migration and osteoclast fusion. FXIII-A 
contributed to these processes through its ability to influence actin dynamics [108], suggesting it 
may also be involved in cytoskeletal-mediated processes in other cell types.  Evidence of FXIII-A 
involvement at the intracellular signalling level in osteoblast calveolae has also been identified in 
mineralised tissues. Calveolae are lipid raft plasma membrane invaginations involved in the 
regulation of endocytosis and intracellular signal transduction, via the clustering of receptors and 
signalling molecules. In differentiating osteoblasts FXIII-A colocalises intracellularly with caveolin-1 
on the inner leaflet of calveolae, where it is involved in intracellular signalling by regulating 
interactions between Cav-1 and c-SRC kinase [109]. This regulatory signalling role in osteoblasts 
suggests that FXIII-A may also be involved in signalling pathways in other cells.   
 
There are divergent reports on the size of FXIII-A in various cell types including those of mineralized 
tissue and adipocytes. In preadipocytes two bands of FXIII-A have been identified, one at the 
expected size of 80 kDa and another of 50-75 kDa [34].  FXIII-A has also been detected as a 37 kDa 
fragment in chondrocytes [110], cultured MC3T3-E1 osteoblast cells [101, 102] primary mouse 
osteoblast cells, mouse macrophage and chondrocyte extracts and in rat bone [101]. The 37 kDa 
fragment, postulated to arise from proteolytic cleavage of the full-length form, has a different 
subcellular localisation to full length FXIII-A in osteoblasts [101]. However, Cordell and colleagues 
[111] suggest that the mAb-AC-1A1 antibody used in these studies cross-reacts with transaldolase-1 
(37 kDA) and other off-target antigens in cultured cells. Furthermore, this 37 kDa band is present in a 
number of cell types that lack FXIII-A protein and mRNA [111] and in bone and heart tissue from 
FXIII-A deficient mice [111]. FXIII-A and TG2 deficient mice also appear to exhibit normal bone 
deposition [111], suggesting that transglutaminase activity is not required for these processes in 
vivo.  It is evident from the tangled literature that further work is necessary to define the forms of 
FXIII-A in bone and confirm its role in the formation, maintenance and repair of mineralized tissues 
in vivo. 
 
Cellular FXIII-A in disease 
The vast number of functions carried out by cellular FXIII-A has inevitably resulted in its contribution 
to a number of different disease states, where it has been found to play beneficial and detrimental 
roles.  
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FXIII-A in lung disease 
Cellular FXIII-A and plasma FXIIIA2B2 have been implicated in the pathogenesis of lung diseases. In 
many forms of acute and chronic lung inflammation, fibrin deposition occurs as a result of increased 
vascular permeability eventually leading to fibrosis [112].  Cellular FXIII-A from injured alveolar 
macrophages and plasma FXIIIA2B2 from leaky capillaries have been detected in the bronchoalveolar 
lavage fluid of children with chronic bronchoalveolar inflammatory conditions, along with D-dimer 
[113].  These data suggest that FXIII is involved in stabilising fibrin deposits in the extravascular 
compartment of the lung tissues in these diseases. Increased FXIII-A release from dendritic cells is 
also detectable in bronchiolar lavage fluid following allergen challenge in asthmatic patients.  This 
suggests a potential role for FXIII-A in airway obstruction in this disease [114], perhaps through the 
reinforcement of fibronectin deposits, which are involved in pathogenic airway remodelling in 
asthma [115].  
 
FXIII-A in vascular disease 
Long-term alterations in blood flow ultimately give rise to vascular remodelling [116], a process in 
which FXIII-A has been implicated [117]. Blood vessel widening occurs in response to increased 
blood flow, decreased blood flow results in vessel narrowing [118, 119] and vessel walls thicken in 
response to high blood pressure [120]. Macrophage FXIII-A may participate in flow-induced 
remodelling of vessels [121].  Zhou et al., [121] demonstrated that expression of the CXCR3 receptor 
is necessary for inward perivascular remodelling induced by alterations in blood flow. This CXCR3-
dependant accumulation of macrophages during perivascular remodelling enhanced expression of 
FXIII-A mRNA [121], suggesting that the transglutaminase may function by stabilizing the remodelled 
vascular wall. 
 
Hypertension is characterized as long term elevation in blood pressure and is a significant risk factor 
for the development of atherosclerosis.  Infiltration of the arterial wall by monocytes, macrophages 
and T-cells leads to formation of new connective tissue, which together with the infiltrating 
leukocytes, forms an atherosclerotic lesion [122]. The angiotensin II (ATII) signalling system is 
involved in multiple regulatory processes, including the control of blood pressure through 
vasoconstriction.  ATII signalling is also implicated in a number of pathological diseases, such as 
hypertension and atherosclerosis [123]. Monocyte FXIII-A plays a pathogenic role in hypertensive 
disease due to its ability to increase the signalling capacity of the angiotensin receptor (ATI) [124].  
ATI receptor dimerization occurs in the presence of ATII, and FXIII-A subsequently facilitates covalent 
cross-linking of the ATI monomers, resulting in increased receptor capacity for signalling and 
desensitization [124]. Hypertensive patients display an increase in both monocyte FXIII-A and 
angiotensin-converting-enzyme (ACE)-dependant ATII production and storage [124]. Increased cross-
linked AT1 dimers have been found in an ApoE-/- model of atherosclerotic mice and inhibition of 
ACE and cellular FXIII-A reduced atherosclerotic lesion area and attenuated the recruitment of 
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leukocytes into the aorta [124].  Platelet-derived FXIII-A has also been identified in atherosclerotic 
plaques [125], suggesting that the function of platelet FXIII-A is not confined to hemostasis and may 
function in pathogenic situations, such as stabilization of atherosclerotic lesions. 
 
FXIII-A in cardiac disease 
Plasma FXIIIA2B2 and platelet FXIII-A have been found to contribute to the integrity of the cardiac 
vessel wall. A number of cardiac pathologies are observed in FXIII deficient mice, most of which are 
exacerbated by the combined absence of both cellular and plasma FXIII [126].  In these cases, 
hemorrhage and fibrosis resulting from lack of plasma FXIIIA2B2 induce initial damage to cardiac 
tissue, this is followed by delayed wound healing, due to the absence of cellular FXIII-A in leukocytes 
in these tissues [126].  FXIII-A is present in resident monocytes and macrophages in normal cardiac 
tissue, and following coronary ligation [127].  FXIII deficient mice exhibit an increased incidence of 
cardiac rupture, which can be circumvented by infusion of FXIIIA2B2, although ventricular 
remodelling in these mice remained diminished [127]. High levels of FXIII transglutaminase activity 
was observed in healing infarct tissue, suggesting its active participation in the wound healing 
response.  A reduction in leukocytes has been documented in cardiac tissue in FXIII-A deficient mice 
[128], which could be attributed to the role of FXIII-A in cell migration, thus exacerbate the impaired 
wound healing observed.     
 
FXIII-A in inflammatory disease  
 
The expression of FXIII-A in a number of inflammatory cells also implicates it in the pathogenesis of 
certain inflammatory disorders.  In ulcerative colitis, reduced expression of both cellular FXIII-A and 
plasma FXIIIA2B2 is evident due to upregulation of the M1 immune response. The reduction of FXIII 
levels in this case will affect its capacity to aid in phagocytosis and cell migration and may contribute 
to the prolongation and severity of the disease [129]. The contribution of FXIII-A to inflammatory 
arthritis is also evident in collagen-induced arthritis models FXIII-A deficient mice.  There was a 
significant reduction in osteoclast differentiation in FXIII-A deficient mice which limited disease 
progression. FXIII-A deficient mice also displayed reduced deposition of fibrin in the extracellular 
spaces within the knee joints leading to a reduction in the retention of inflammatory macrophages 
[130].  These results clearly show that eliminating FXIII-A limits inflammatory arthritis and protects 
from cartilage and bone destruction, thus suggesting that inhibition of this transglutaminase is a 
potential therapeutic strategy in arthropathies and other degenerative bone diseases.  
 
FXIII-A in diabetes and obesity 
Pancreatic islet  cells harbours FXIII-A which exerts transglutaminase activity in response to 
prolonged spikes in cytosolic Ca2+ [131].  Glucose-stimulated insulin secretion in -cells is inhibited 
upon treatment with a transglutaminase inhibitor, suggesting that FXIII-A activity is involved in 
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insulin regulation [131].  Interestingly, a recent study has identified a possible connection between 
FXIII-A and type 2 diabetes in a mouse model of obesity-induced chronic low-grade inflammation, 
mimicking that found in type 2 diabetes [132].  Mice treated with low dose pro-inflammatory 
cytokines exhibited reduced glucose-stimulated insulin secretion and increased basal Ca2+ levels, 
resulting in reduced expression of the FXIII-A gene (F13A1) [132].  Identification of F13A1 as a novel 
stress-inhibited gene in islets provides a promising lead to pursue in the dysfunction that occurs in 
these cells during the development of type 2 diabetes. 
 
Single nucleotide polymorphisms SNPs in F13A1 correlate with increased body mass index and an 
increased incidence of type 2 diabetes [133].  A recent study performed by Myneni et al., [34] 
suggests that FXIII-A may contribute to obesity and weight gain.  FXIII-A is expressed in adipose 
tissue where it is enhances proliferation of preadipocytes and stabilises the fibronectin matrix. [34].  
In line with these observations, FXIII-A deficient mice are protected against insulin resistance, they 
show signs of metabolically healthy obesity [134].  Further work is urgently required to clarify the 
direct role of FXIII-A in attenuating type 2 diabetes and obesity. 
 
FXIII-A in cancer 
FXIII-A has been identified in a number of leukemic cell types including megakaryoblasts, 
promyeloblasts, monoblasts and lymphoblasts[135, 136] and FXIII-A expression in leukemic cells is 
associated with reduced patient survival in acute promyelocytic leukemia [137]. In contrast, a recent 
study has shown that FXIII-A expression in children with B-cell precursor acute lymphoblastic 
leukemia was associated with patient survival [138]. Further studies in this area are essential to 
delineate the role of FXIII-A in leukemic cells in contributing towards disease progression.   
 
Summary and future perspectives 
Plasma FXIIIA2B2 was classified as a coagulation factor in the 1960’s and is largely found in complex 
with the precursor of its principal target protein, fibrinogen.  The clear bleeding phenotype of 
individuals deficient in FXIII is testimony to its essential function in hemostasis.  However, there has 
been ambiguity surrounding the true function of the cellular form of FXIII-A.  This can in part be 
ascribed to the fact that while FXIII-A is expressed by numerous cell types, mainly those of 
hematopoietic origin, it does not contain a classical endoplasmic reticulum signal peptide for 
secretion in nucleated cells [11].  This has hampered research into FXIII-A, but accumulating 
evidence now indicates that it is a diverse cellular enzyme that cross-links numerous substrates 
within the intracellular and extracellular environment (summarised in Figure 2).  Recent 
observations accrediting the cellular source of the plasma FXIII-A subunit to resident tissue 
macrophages [15] has significantly advanced our knowledge, but as yet the mechanism involved in 
its secretion remain an enigma.  Given the nature of this enzyme, and the fact that isopeptide bonds 
can be formed between glutamine donors and lysine acceptor residues in a wide range of proteins, it 
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is perhaps not surprising that FXIII-A functions in such an array of biological processes.  Nonetheless, 
the absence of an inhibitor of FXIII-A suggests that the environment and kinetics of this 
transamidase enzyme must regulate its function, but direct evidence on this is scant.  In conclusion, 
it is evident that FXIII-A is a broad spectrum enzyme that is largely indiscriminate in its ability to 
cross-link protein substrates, but there is still much to be uncovered in relation the mechanism of 
secretion from cells of bone marrow lineage and direction of its function in different biological and 
pathophysiological processes.   
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Legends 
Figure 1:  Platelets externalise FXIII-A during activation.  (A) Washed platelets (5 x 107/ml) were left 
unstimulated or activated with 20 g/ml collagen/ 20 M TRAP-6 and stained using FITC-labelled 
anti-FXIII-A antibody (green) and Alexa-fluor®647 Annexin-V to detect phosphatidylserine (red).  A 
time course of activation is shown.  Scale bar represents 10 M. (B) Platelets were stimulated and 
FXIII-A and annexin detected as described in (A).  Images focus on phosphatidylserine (PS)-positive 
and PS-negative staining.  Scale bar represents 5 M. Representative images of n=4 separate 
experiments.  (C) Three dimensional reconstructions of platelets stimulated as above showing PS-
positive platelets (red) with FXIII-A (green) concentrated in the ‘cap’.  PS-negative platelets that stain 
only for FXIII-A can also be visualised.  Images were recorded on a Zeiss LSM70 confocal microscope 
with 63x 1.40 oil immersion objective and analyzed using Zen 2012 software. 
Figure 2:  Extracellular functions of cellular FXIIII-A.  FXIII-A is expressed primarily in cells of bone 
marrow lineage and is now appreciated to function in many extracellular processes from 
phagocytosis to stabilization of bone.  The range of its extracellular functions intimately aligns with 
the expression of the FXIII-A gene (F13A1) in hematopoietic stem cells.      
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